Antiphospholipid syndrome in pregnancy.
During the past 5 years the author and his colleagues have assessed carefully 351 women referred for evaluation of thrombosis and hemostasis after they had suffered recurrent miscarriages. This article describes the flow protocol the author and associates follow to maximize success and keep the costs of evaluation of recurrent miscarriage syndrome/infertility at a minimum while providing the best chances for defining a cause and thus providing optimal therapy for successful term pregnancy outcome. It presents the outcomes of the author's protocol and those of others in treating women who have antiphospholipid syndrome and who have suffered recurrent miscarriages.
Bick
Rodger L
RL
rbick@thromosis.com
D000026:Abortion, Habitual / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D017152:Antibodies, Antiphospholipid / Q000276:immunology / Q000502:physiology; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D001241:Aspirin / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000276:immunology* / Q000503:physiopathology; D019851:Thrombophilia / Q000276:immunology / Q000503:physiopathology
D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin; D001241:Aspirin